share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  11/13 07:48

Moomoo AI 已提取核心訊息

Cybin Inc., a clinical-stage neuropsychiatric company, filed its Form 6-K with the United States Securities and Exchange Commission for November 2024, reporting its interim consolidated financial statements for the three and six months ended September 30, 2024. The unaudited financial statements, prepared in accordance with International Accounting Standards, show a net loss of $57.2 million for the quarter and $72.0 million for the six-month period, compared to $11.9 million and $26.4 million for the same periods in 2023, respectively. The company's total assets decreased to $262.4 million from $302.0 million as of March 31, 2024. The report, signed by CEO Doug Drysdale on November 13, 2024, also includes management's discussion and analysis, certifications by the CEO and CFO, and a news release. Cybin's shares are traded on the NYSE American LLC under the symbol 'CYBN'. The company, which focuses on advancing therapies for psychiatric and neurological conditions, has seen an increase in research expenses and share-based compensation during the reported periods.
Cybin Inc., a clinical-stage neuropsychiatric company, filed its Form 6-K with the United States Securities and Exchange Commission for November 2024, reporting its interim consolidated financial statements for the three and six months ended September 30, 2024. The unaudited financial statements, prepared in accordance with International Accounting Standards, show a net loss of $57.2 million for the quarter and $72.0 million for the six-month period, compared to $11.9 million and $26.4 million for the same periods in 2023, respectively. The company's total assets decreased to $262.4 million from $302.0 million as of March 31, 2024. The report, signed by CEO Doug Drysdale on November 13, 2024, also includes management's discussion and analysis, certifications by the CEO and CFO, and a news release. Cybin's shares are traded on the NYSE American LLC under the symbol 'CYBN'. The company, which focuses on advancing therapies for psychiatric and neurological conditions, has seen an increase in research expenses and share-based compensation during the reported periods.
臨床階段的神經精神疾病公司Cybin Inc.向美國證券交易委員會提交了2024年11月的6-k表格,報道截至2024年9月30日的三個月和六個月的內部合併財務報表。 根據國際會計準則編制的未經審計財務報表顯示,截至季度末公司錄得570萬美元的淨虧損,爲同期的1190萬美元和2640萬美元的六個月的相應金額的7200萬美元。 截至2024年3月31日,公司的總資產從30200萬美元減少到26240萬美元。 報告由CEO Doug Drysdale在2024年11月13日簽署,還包括管理層討論和分析、CEO和CFO的認證以及一則新聞發佈。 Cybin的股票在紐約證券交易所美國有限責任公司(NYSE American LLC)以'CYBN'爲標的物進行交易。 這家專注於推進精神疾病和神經疾病治療的公司,在報告期內研究費用和股權報酬出現增加。
臨床階段的神經精神疾病公司Cybin Inc.向美國證券交易委員會提交了2024年11月的6-k表格,報道截至2024年9月30日的三個月和六個月的內部合併財務報表。 根據國際會計準則編制的未經審計財務報表顯示,截至季度末公司錄得570萬美元的淨虧損,爲同期的1190萬美元和2640萬美元的六個月的相應金額的7200萬美元。 截至2024年3月31日,公司的總資產從30200萬美元減少到26240萬美元。 報告由CEO Doug Drysdale在2024年11月13日簽署,還包括管理層討論和分析、CEO和CFO的認證以及一則新聞發佈。 Cybin的股票在紐約證券交易所美國有限責任公司(NYSE American LLC)以'CYBN'爲標的物進行交易。 這家專注於推進精神疾病和神經疾病治療的公司,在報告期內研究費用和股權報酬出現增加。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息